Evidence map›Paper›PMID 33225099›Full record

ReviewJMA journal2020

Research and Development Strategy for Future Embryonic Stem Cell-Based Therapy in Japan.

Akihiro Umezawa, Yoji Sato, Shinji Kusakawa, Rin Amagase, Hidenori Akutsu, Kazuaki Nakamura, Mureo Kasahara, Yoichi Matsubara, Takashi Igarashi

Open access · diamondAbstract readReview
In one paragraph

Review in JMA journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Akihiro UmezawaCenter for Regenerative Medicine, National Center for Child Health and Development, Tokyo, Japan.
Yoji SatoDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kawasaki, Japan.
Shinji KusakawaDivision of Cell-Based Therapeutic Products, National Institute of Health Sciences, Kawasaki, Japan.
Rin AmagaseCenter for Regenerative Medicine, National Center for Child Health and Development, Tokyo, Japan.
Hidenori AkutsuCenter for Regenerative Medicine, National Center for Child Health and Development, Tokyo, Japan.
Kazuaki NakamuraCenter for Regenerative Medicine, National Center for Child Health and Development, Tokyo, Japan.
Mureo KasaharaOrgan Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.
Yoichi MatsubaraNational Center for Child Health and Development Research Institute, Tokyo, Japan.
Takashi IgarashiNational Center for Child Health and Development, Tokyo, Japan.
National Center For Child Health and Development · JPNational Institute of Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herewith, we review an updated progress of regenerative medical products using human embryonic stem cells (ESCs) in Japan. Two groups from Kyoto University and the National Center for Child Health and Development (NCCHD) established a novel derivation/cultivation system of ESCs for potential application in translational and clinical research. At the first stage of ESC derivation, murine feeder cells have been used in line with Japanese guidelines on public health associated with the implementation of the xenograft. To avoid exposure of ESCs to animal products in culture media, a xeno-free cultivating system has been established. Twelve ESCs (KhES-1, KhES-2, KhES-3, KhES-4, KhES-5, SEES-1, SEES-2, SEES-3, SEES-4, SEES-5, SEES-6, and SEES-7) are now available under a clinically relevant platform for industrially and clinically applicable regenerative medical products. NCCHD submitted an investigative new drug application to the Pharmaceuticals and Medical Devices Agency (PMDA) for using ESC-based products in patients with hyperammonemia due to genetic defects on March 2018 under the Pharmaceutical Affairs Law (now revised to the Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act). Currently, up to ten ESC-based products are being prepared for intractable and rare disorders in Japan.

Indexed as

and Other Therapeutic Products Actembryonic stem cellsESCsMedical DevicesPharmaceuticalsregulationThe Act on the Safety of Regenerative Medicine

Identifiers

PMID33225099
PMCPMC7676987
OpenAlexW3110278418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.